User login
Non-persistence to prophylactic treatment was frequent among migraine patients, a recent study found. Furthermore, opioid use was common in migraine patients and the risk of gastrointestinal-related adverse events and opioid abuse increased with long-term use of opioids. These results suggest a need for more effective prophylactic migraine treatments. This study used the IBM MarketScan databases from 2005 through 2014 to evaluate migraine patients initiating prophylactic medication. In total, 147,832 patients were analyzed. Outcome measures included persistence with prophylactic migraine medications throughout 2 to 5 years. Acute medication use and gastrointestinal-related adverse events and opioid abuse following opioid use were evaluated. Researchers found:
- Non-persistence was observed in 90% of patients; 39% switched, 30% restarted, and 31% discontinued treatment.
- Throughout the follow-up, 59.9% of patients received triptans, 66.6% non-steroidal anti-inflammatory drugs, 77.4% opioids, and 2.6% ergotamines.
- Among opioid users, 16.6% experienced nausea/vomiting, 12.2% had constipation, and 10.4% had diarrhea.
- Opioid abuse was reported in <1% of opioid users.
- Gastrointestinal-related adverse events increased with increasing number of days’ supply of opioids.
Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. [Published online ahead of print February 28, 2019]. Cephalalgia. doi:10.1177%2F0333102419835465.
Non-persistence to prophylactic treatment was frequent among migraine patients, a recent study found. Furthermore, opioid use was common in migraine patients and the risk of gastrointestinal-related adverse events and opioid abuse increased with long-term use of opioids. These results suggest a need for more effective prophylactic migraine treatments. This study used the IBM MarketScan databases from 2005 through 2014 to evaluate migraine patients initiating prophylactic medication. In total, 147,832 patients were analyzed. Outcome measures included persistence with prophylactic migraine medications throughout 2 to 5 years. Acute medication use and gastrointestinal-related adverse events and opioid abuse following opioid use were evaluated. Researchers found:
- Non-persistence was observed in 90% of patients; 39% switched, 30% restarted, and 31% discontinued treatment.
- Throughout the follow-up, 59.9% of patients received triptans, 66.6% non-steroidal anti-inflammatory drugs, 77.4% opioids, and 2.6% ergotamines.
- Among opioid users, 16.6% experienced nausea/vomiting, 12.2% had constipation, and 10.4% had diarrhea.
- Opioid abuse was reported in <1% of opioid users.
- Gastrointestinal-related adverse events increased with increasing number of days’ supply of opioids.
Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. [Published online ahead of print February 28, 2019]. Cephalalgia. doi:10.1177%2F0333102419835465.
Non-persistence to prophylactic treatment was frequent among migraine patients, a recent study found. Furthermore, opioid use was common in migraine patients and the risk of gastrointestinal-related adverse events and opioid abuse increased with long-term use of opioids. These results suggest a need for more effective prophylactic migraine treatments. This study used the IBM MarketScan databases from 2005 through 2014 to evaluate migraine patients initiating prophylactic medication. In total, 147,832 patients were analyzed. Outcome measures included persistence with prophylactic migraine medications throughout 2 to 5 years. Acute medication use and gastrointestinal-related adverse events and opioid abuse following opioid use were evaluated. Researchers found:
- Non-persistence was observed in 90% of patients; 39% switched, 30% restarted, and 31% discontinued treatment.
- Throughout the follow-up, 59.9% of patients received triptans, 66.6% non-steroidal anti-inflammatory drugs, 77.4% opioids, and 2.6% ergotamines.
- Among opioid users, 16.6% experienced nausea/vomiting, 12.2% had constipation, and 10.4% had diarrhea.
- Opioid abuse was reported in <1% of opioid users.
- Gastrointestinal-related adverse events increased with increasing number of days’ supply of opioids.
Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. [Published online ahead of print February 28, 2019]. Cephalalgia. doi:10.1177%2F0333102419835465.